Characterization and changing minimum inhibitory concentration (MIC) of Acinetobacter species from a tertiary care setup

Journal of Communicable Diseases

Volumn 37, Issue 2, 2005, Pages 99-107

  Capoor, M R ^a   Nair, D ^a   Srivastava, L ^a   Gupta, B ^a   Aggarwal, P ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

Acinetobacter spp.; Biotyping; MIC; Resistotyping

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM;

ACINETOBACTER; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; BACTERIUM IDENTIFICATION; CLASSIFICATION; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; TREATMENT OUTCOME;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; BETA-LACTAMS; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33646248886     PISSN: 00195138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Joly-Guillou ML, Bergogne-Berezin E and Vieu JF. A study of the relationships between antibiotic resistance phenotypes, phage typing and biotyping of 117 clinical isolates of Acinetobacter spp. J Hosp Infect 1990; 16: 49-58.
2. Bergogne-Berezin E. Acinetobacter spp., saprophytic organisms of increasing pathogenic importance. Int J Med Microbiol Virol Parasitol Infect Dis 1994; 281(4): 389-405.
3. Gales AC, Jones RN, Forward KR, Linares J, Sacher HS and Verchoel J. Emerging importance of Multidrug - Resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns epidemiological features and trends in the sentry antimicrobial surveillance program (1997-1999). Clin Infect Dis 2001; 32(2): 104-113.
4. Wang SH, et al. Healthcare associated outbreak due to pan-drug resistant Acinetobacter baumanii in a surgical intensive care unit J Hosp Infect 2003; 53(2): 97-102.
5. Wang JT, McDonald LT, Chang SC and Ho M. Community acquired Acinetobacter baumanii bacteraemia in adult patients in Taiwan. J Clin Microbiol 2002; 40: 1526-1529.
6. Bergogne-Berzin E. The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents. J Hosp Infect 1995; 30: 441-452.
7. Anstey NM, Currie BJ and Withnall KM. Community acquired Acinetobacter pneumonia in the northern territory of Australia. Clin Infect Dis 1992; 14: 83-91.
8. Cordes IG, Brink EW, Checko PJ et al. Cluster of Acinetobacter pneumonia in foundry workers. Ann Intern Med 1959; 95: 688-693.
9. Click LM, Moran GP, Coleman JM and O'Brien GF. Lobar pneumonia with bacteraemia caused by Bacterium anitratum. Am J Med 1959; 27: 183-186.
10. Goodhart GL, Brutyn E, Watson RK, Root and Egert. Community acquired Acinetobacter calcoaceticus var. anitratus pneumonia. JAMA 238: 1516-1518.
11. Jawad A, Seifert H, Suelling AM, Heritage J and Hawkey PM. Survival of Acinetobacter baumannii on dry surfaces: Comparison of outbreak and sporadic isolates. J Clin Microbiol 1998; 36(7): 1938-1941.
12. Bergogne-Berezin A and Towner KJ. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical and epidemiological factors. Clin Microbiol Rev 1996; 9: 148-165.
13. Aswapokee N, Tiengrim S, Charoensook B and Sangiriwut K. Antimicrobial resistant pattern of Acinetobacter spp. J Infect Dis Antimicrob Agents 1998; 2: 43-48.
14. Okpara Au and Maswoswe JJ. Emergence of multidrug-resistant isolates of Acinetobacter baumannii. Am J Hosp Pharm 1994; 51(21): 2671-2675.
15. Towner KJ. Acinetobacter. In Topley and Wilsons, Collier L, Balows A, Sussman M Eds: Microbiology and microbial infections, New York: Arnold, 1999 (9ed), 1229-1237.
16. Vahaboglu H, Ozturk R, Aygum G et al. Widespread detection of PER - I type extended spectrum betalactamases among nosocomial Acinetobacter and Ps. aeruginosa isolates in Turkey a nationwide multicentre study. Antimicrob Agents Chemother 1997; 41 (10): 2265-2269.
17. Takahashi A, Komodo S, Kobayashi J, Okubo T, Tuned M and Isobel S. Detection of carbapenemase producing Acinetobacter baumannii in a hospital. J Clin Microbial 2000; 38(2): 526-529.
18. Towner KJ. Clinical importance and antibiotic resistance of Acinetobacter spp. J Clin Microbiol 1997; 46: 721-746.
19. Gerner-Smidt P and Tjernberg I, Reliability of phenotypic tests for identification of Acinetobacter spp. J Clin Microbiol 1991; 29: 277-282.
20. th edn. Washington, DC: American Society for Microbiology 2003; 749-771.
21. National Committee for Clinical Laboratory Standards 2002. Performance standards for antimicrobial susceptibility testing 12 supplement. M100-S7. NCCLS, Wayne, Pa
22. Aktas O and Ozbek A. Prevalence and in-vitro antimicrobial susceptibility patterns of Acinetobacter strains isolated from patients in intensive care units. J Int Med Res 2003; 31(4): 272-280.
23. Spence RP, Towner KJ, Henwood CJ, James D, Woodford N and Livemore DM. Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13 Tu isolates from hospitals in the UK. J Med Microbiol 2002; 51(12): 1107-1112.
24. Traub WH and Spour M. Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3 and genospecies 6). Antimicrob Agents Chemother 1989; 33: 1617-1619.
25. Prasanth K and Badrinath S. Simplified panel of assimilation tests for identification of Acinetobacter species. Indian J Pathol Microbiol 2003; 46(4): 700-706.
26. Kaplan NE, Rosenberg E, Jann B and Jann K structural studies of the capsular polysaccharide of Acinetobacter calcoaceticus BD4. Eur J Biochem 1985; 152: 453-458.
27. Gerner-Smidt P and Frederiksen W. Acinetobacter in Denmark: I Taxonomy, antibiotic susceptibility and pathogenecity of 112 clinical strains. Acta Pathol Microbiol Immunol Scand 1993; 101(11): 815-825.
28. Prasanth K and Badrinath S. In vitro susceptibility pattern of Acinetobacter species to commonly used cephalosporins, quinolones, and aminoglycosides. Ind J Med Microbiol 2004; 22(2): 97-103.